Combining glecirasib and sitneprotafib shows encouraging efficacy and safety in patients with KRAS G12C-mutated NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback